What is Daktari Diagnostics?
Daktari Diagnostics operates at the intersection of advanced medical technology and clinical diagnostics. The company is dedicated to developing innovative, point-of-care diagnostic solutions designed to address critical unmet needs in global health. By leveraging sophisticated engineering and biological insights, Daktari Diagnostics aims to decentralize diagnostic testing, allowing for rapid, accurate results in diverse clinical settings. Its market position is defined by a commitment to improving patient outcomes through accessible, high-performance diagnostic tools that bridge the gap between laboratory-grade precision and field-level utility.
How much funding has Daktari Diagnostics raised?
Daktari Diagnostics has raised a total of $79.1M across 8 funding rounds:
Series A
$2.8M
Private Equity
$820K
Private Equity
$1.8M
Debt
$1.2M
Series B
$10M
Private Equity
$20M
Series C
$20M
Series D
$22.5M
Series A (2009): $2.8M with participation from LaunchPad Venture Group, Hub Angels Investment Group, Mass Medical Angels, Norwich Ventures, and Boston Harbor Angels
Private Equity (2010): $820K, investors not publicly disclosed
Private Equity (2010): $1.8M, investors not publicly disclosed
Debt (2011): $1.2M, investors not publicly disclosed
Series B (2011): $10M backed by Merck & Co and Norwich Ventures
Private Equity (2013): $20M with participation from Norwich Ventures
Series C (2014): $20M, investors not publicly disclosed
Series D (2015): $22.5M supported by Norwich Ventures and Merck Global Health Innovation Fund
Key Investors in Daktari Diagnostics
Norwich Ventures
Norwich Ventures is a specialized venture capital firm established in 2004, focusing on early-stage medtech investments. The firm seeks to support entrepreneurs developing innovative technologies that address significant unmet medical needs.
Merck Global Health Innovation Fund
Founded in 1891 and headquartered in Rahway, NJ, Merck & Co., Inc. is a global healthcare company delivering innovative solutions through prescription medicines, biologic therapies, vaccines, and animal health products.
Mass Medical Angels
Mass Medical Angels (MA2) is a seed stage investor group focused on life science and healthcare investments, aiming to bring clinical tools to the marketplace while achieving superior returns for investors.
What's next for Daktari Diagnostics?
With the recent strategic investment, Daktari Diagnostics is well-positioned to scale its operations and deepen its market penetration. The company is expected to prioritize the commercialization of its diagnostic pipeline, focusing on regulatory milestones and the expansion of its distribution networks. Furthermore, the infusion of capital will likely support ongoing research and development initiatives, ensuring the firm remains at the forefront of diagnostic innovation. As the company enters this next phase of growth, the focus will shift toward operational efficiency and the long-term sustainability of its business model in an increasingly competitive healthcare environment.
See full Daktari Diagnostics company page
